Akari Therapeutics' (AKTX) shares skyrocket 175% after 'successful' pre-IND FDA meeting

NASDAQ: AKTX | Akari Therapeutics Plc News, Ratings, and Charts

AKTX – Shares of Akari Therapeutics PLC more than doubled, toward a 15-month high in very active morning trade Wednesday.


Shares of Akari Therapeutics PLC AKTX, +196.14% more than doubled–soaring 145%–toward a 15-month high in very active morning trade Wednesday, enough to pace all the gainers on the Nasdaq exchange, after the company said it plans to commence trials in European and U.S. pediatric patients this year for its treatment of pediatric thrombotic microangiopathy. Trading volume rocketed to 22.3 million shares, compared with the full-day average of about 20,000 shares. The company said it had a “successful,” pre-investigational new drug (IND) meeting with the Food and Drug Administration regarding its pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), which is an orphan condition with an estimated fatality rate of 80%. Chief Executive Clive Richardson said trials in HSCT-TMA patients are planned to begin in the fourth quarter. “We see HSCT-TMA as a gateway indication into a range of other poorly treated orphan TMAs, and are enthusiastic about the potential of Coversin to offer an improved standard of care for patients with these rare and usually fatal conditions,” Richardson said. The stock has now run up 93% over the past 12 months, while the iShares Nasdaq Biotechnology ETF IBB, +1.19% has slipped 1.1% and the S&P 500 SPX, +0.87%gained 0.9%.


Akari Therapeutics PLC ADR shares were trading at $4.80 per share on Wednesday morning, up $2.98 (+163.74%). Year-to-date, AKTX has gained 205.73%, versus a 12.66% rise in the benchmark S&P 500 index during the same period.

AKTX currently has a StockNews.com POWR Rating of D (Sell), and is ranked #180 of 315 stocks in the Biotech category.


This article is brought to you courtesy of MarketWatch.

AKTX at a Glance

AKTX Current POWR Rating™
Overall POWR Rating™
AKTX Current Price $4.10 8.89%
More AKTX Ratings, Data, and News

AKTX Price Reaction

The day of this event (Mar. 13, 2019)
AKTX Closing Price$5.90 224.16%
AKTX Volume81,390,800
145,101.41% from avg
Leading up to this event
AKTX 1-mo return4.21%
After this event
AKTX 1-day return68.62%
AKTX 3-day return60.17%
AKTX 5-day return55.61%

AKTX Price Chart



More Akari Therapeutics Plc (AKTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AKTX News
Page generated in 0.5771 seconds.